Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab...
-- Yescarta Results in a 27.4% Reduction in Risk of Death, Corresponding to a 38% Relative Improvement in OS, Despite 57% of Patients Subsequently Receiving Cell Therapy Off...
High dividend-paying stocks are down 7% this year versus gains of 9% and 26% for the S&P 500 and Nasdaq, respectively. Now, it is time for investors to prepare for them to rebound,...
Stagflation remains one of the primary risks for the global economy in 2023. The stock market’s trajectory will continue to be dictated by worries over persistently high...
The stock market appears to have spent the vast majority of the last week or so doing, well, a lot of nothing. In short, the S&P 500 has moved up into the high end of the recent...
The pharmaceutical industry is a top investment option, with the sector experiencing rapid growth in recent years. The COVID-19 pandemic has also shifted the market focus to the...
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, and Stribild. The Company’s COVID-19 product is Veklury. The Company’s also provides Epclusa, Harvoni, Vemlidy, and Viread products for liver diseases. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The Company’s other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.
| Average | 92.08 (+18.48% Upside) |
| High | 115.00 |
| Low | 77.00 |
| Price | 77.72 |
| No. of Analysts | 29 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Sell | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 10.50 | 10.51 | 10.49 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 0.0001 | 0.0001 | 0.0001 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 391.71 | 395.65 | 387.07 | -1.56 | -0.40% | 39.36M | NASDAQ | |||
| 9.48 | 9.50 | 9.48 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 25.0101 | 25.02 | 25.01 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 17.67 | 17.82 | 17.45 | +0.06 | +0.34% | 120.27K | NYSE | |||
| 38.00 | 38.01 | 37.95 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 0.22 | 0.22 | 0.20 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 33.25 | 34.09 | 33.14 | -0.87 | -2.55% | 24.64K | NYSE | |||
| 0.44 | 0.45 | 0.411 | -0.007 | -1.57% | 1.14M | OTC Markets | |||
| 5.91 | 5.92 | 5.90 | +0.01 | +0.17% | 31.99K | OTC Markets | |||
| 0.0001 | 0.0001 | 0.0001 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 7.30 | 7.30 | 7.23 | +0.08 | +1.11% | 7.82K | NYSE | |||
| 0.36 | 0.362 | 0.35 | 0.00 | 0.00% | 198.44K | OTC Markets | |||
| 16.01 | 16.01 | 15.99 | 0.00 | 0.00% | 0.00 | NYSE |